Unum Therapeutics Inc. (UMRX) Tops Q4 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 28, 2019 7:00 AM EDT- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study -
- Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma -
- First Solid Tumor Trial, ATTCK-34-01, Initiated in HER2+ Advanced Cancers
- Expanding Solid Tumor Pipeline with BOXR1030 Advancing as the First Product Candidate from the BOXR Platform
- Extended Cash Runway into Early 2021 -
CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:... More
